ArticleJournal of the American College of Cardiology2005
Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.
Article in Journal of the American College of Cardiology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06675994 (Evaluation of PCSK9 Enzyme in Non-Cholesterol Biological Pathways), which is not on this map. Cited by 135 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of PCSK9 Enzyme in Non-Cholesterol Biological Pathways: In Vitro Demonstration of Direct Platelet-Related Effects of PCSK9 Enzyme
Who cites it
135 citing papers in PubMed, 1 synthesis or guideline pooled it, 647 citations in OpenAlex.
- The Influence of Environmental Hypoxia on Hemostasis-A Systematic Review.Frontiers in cardiovascular medicine · 2022Pooled it
- Trial
- Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case-control study.Journal of thrombosis and thrombolysis · 2020Trial
- Optimal strategy of switching from clopidogrel to ticagrelor in Chinese acute coronary syndrome patients with complicated coronary artery disease: the switching from clopidogrel to ticagrelor (SHIFT-CACS) study.Chinese medical journal · 2019Trial
- Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study).European journal of clinical pharmacology · 2019Trial
- Trial
- Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study.Journal of thrombosis and thrombolysis · 2015Trial
- Trial
- Trial
- Effect of clopidogrel discontinuation at 1 year after drug eluting stent placement on soluble CD40L, P-selectin and C-reactive protein levels: DECADES (Discontinuation Effect of Clopidogrel After Drug Eluting Stent): a multicenter, open-label study.Journal of thrombosis and thrombolysis · 2009Trial
- Interaction between cigarette smoking and clinical benefit of clopidogrel.Journal of the American College of Cardiology · 2009Trial
- Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies.Nature reviews. Cardiology · 2026Review
- Thromboelastography to Support Clinical Decision Making in Patients with Peripheral Artery Disease.Diagnostics (Basel, Switzerland) · 2025Article
- Platelet Reactivity and Fibrin Clot-Strength as assessed by TEG in Patients with Atrial Fibrillation undergoing Percutaneous Coronary Intervention.Journal of cardiovascular translational research · 2025Article
- Role of thromboelastography in predicting stroke risk after endovascular treatment for symptomatic intracranial atherosclerotic stenosis.European journal of medical research · 2025Article
- Changes in platelet maturity and reactivity following acute ST-segment elevation myocardial infarction.Research and practice in thrombosis and haemostasis · 2025Article
- New interest in fibrinogen as an ischemic risk factor.Journal of thrombosis and thrombolysis · 2024Article
- The effect of Mycobacterium tuberculosis treatment on thrombelastography-assessed haemostasis: a prospective cohort study.Thrombosis journal · 2024Article
- Does one size really fit all? The case for personalized antiplatelet therapy in interventional cardiology.Future cardiology · 2024Review
- Cell Surface Platelet Tissue Factor Expression: Regulation by P2YArteriosclerosis, thrombosis, and vascular biology · 2023Article
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesWe investigated the relation of high ex vivo platelet reactivity, rapid fibrin generation, and high thrombin-induced clot strength to postdischarge ischemic events in patients undergoing percutaneous coronary intervention (PCI).
backgroundHigh platelet reactivity and rapid fibrin generation may affect the incidence of ischemic events after PCI. However, limited data is available to link these ex vivo markers to the occurrence of events.
methodsWe measured platelet reactivity to adenosine diphosphate (ADP) by light transmittance aggregometry (LTA) in patients undergoing PCI (n = 192). Clot strength, a measure of thrombin-induced fibrin and platelet interactions, and the time to initial fibrin generation, a marker of thrombin activity, were measured by thrombelastography. The relation of these measurements to ischemic event occurrence was prospectively examined over six months.
resultsA total of 100% and 84% of patients were on aspirin and clopidogrel therapy, respectively, at the time of the initial event. Posttreatment ADP-induced aggregation by LTA (63 +/- 12% vs. 56 +/- 15%, p = 0.02) and clot strength (MA) were higher (74 +/- 5 mm vs. 65 +/- 4 mm, p < 0.001) and time to initial fibrin generation was shorter (4.3 +/- 1.3 min vs. 5.9 +/- 1.5 min, p < 0.001) in patients with events (n = 38). The event rates in the highest quartiles of LTA and MA were 32% and 58%, respectively.
conclusionsHigh platelet reactivity and clot strength, and rapid fibrin formation are novel risk factors for ischemic events after PCI. Clot strength is more predictive than ADP-induced platelet aggregation and may explain the occurrence of events despite treatment with cyclooxygenase-1 and P2Y12 inhibitors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.